Sinopharm Financial Statements From 2010 to 2025
| X2S Stock | EUR 2.26 0.03 1.31% |
Check Sinopharm Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sinopharm Group's main balance sheet or income statement drivers, such as , as well as many indicators such as . Sinopharm financial statements analysis is a perfect complement when working with Sinopharm Group Valuation or Volatility modules.
Sinopharm |
Sinopharm Group Co Company Total Asset Analysis
Sinopharm Group's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Sinopharm Group Total Asset | 335.41 B |
Most of Sinopharm Group's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinopharm Group Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, Sinopharm Group Co has a Total Asset of 335.41 B. This is much higher than that of the Other sector and significantly higher than that of the Other industry. The total asset for all Germany stocks is notably lower than that of the firm.
Sinopharm Group Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sinopharm Group's current stock value. Our valuation model uses many indicators to compare Sinopharm Group value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sinopharm Group competition to find correlations between indicators driving Sinopharm Group's intrinsic value. More Info.Sinopharm Group Co is rated fourth in current valuation category among its peers. It is rated below average in price to book category among its peers . The ratio of Current Valuation to Price To Book for Sinopharm Group Co is about 17,937,579,674 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sinopharm Group's earnings, one of the primary drivers of an investment's value.About Sinopharm Group Financial Statements
Sinopharm Group stakeholders use historical fundamental indicators, such as Sinopharm Group's revenue or net income, to determine how well the company is positioned to perform in the future. Although Sinopharm Group investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sinopharm Group's assets and liabilities are reflected in the revenues and expenses on Sinopharm Group's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sinopharm Group Co. Please read more on our technical analysis and fundamental analysis pages.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Sinopharm Stock
Sinopharm Group financial ratios help investors to determine whether Sinopharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sinopharm with respect to the benefits of owning Sinopharm Group security.